Social, cultural and economic aspects of antimicrobial resistance
Bull World Health Organ
2020 Dec 1;98(12):823-823A.
Susan Rogers Van Katwyk
Pedro Henrique D Batista
Clare I R Chandler
Aaron S Kesselheim
Michael T Osterholm
Steven J Hoffman
Center for Advanced Studies in Biomedical Innovation Law, University of Copenhagen, Copenhagen, Denmark.
Social Innovation on Drug Resistance, Boston University, Boston, United States of America (USA).
Global Strategy Lab, Faculty of Health and Osgoode Law School, York University, 4700 Keele Street, Dahdaleh Building, Suite 2120, Toronto, Ontario, M3J 1P3, Canada.
Max Planck Institute for Innovation and Competition, Munich, Germany.
Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, England.
Department of Business Studies, Uppsala University, Uppsala, Sweden.
Antimicrobial Stewardship Program, Geneva University Hospitals, Geneva, Switzerland.
Program on Regulation, Therapeutics, and Law, Harvard Medical School and Brigham and Women's Hospital, Boston University, Boston, USA.
Center for Disease Dynamics, Economics & Policy, Washington, DC, USA.
Centre for Law, Medicine and Life Sciences, University of Cambridge, Cambridge, England.
Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, USA.
Milken Institute School of Public Health, George Washington University, Washington, DC, USA.
No abstract available
Drug Resistance, Bacterial*